Sigyn Therapeutics (SIGY) Non Operating Income (2017 - 2025)
Sigyn Therapeutics (SIGY) posted Non Operating Income of -$191974.0 for Q3 2025, up 80.44% sequentially from -$981674.0 in Q2 2025, and up 50.58% YoY from -$127488.5 in Q3 2024.
Sigyn Therapeutics (SIGY) Non Operating Income (2017 - 2025) Analysis & Trends
Sigyn Therapeutics has reported Non Operating Income for 9 years, with the latest figure at -$191974.0 in Q3 2025.
- Quarterly Non Operating Income rose 50.58% year-over-year to -$191974.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was -$1.3 million (down 8.58% YoY) and the FY2024 annual result came in at -$820970.0, up 51.44% from the prior year.
- Non Operating Income rose to -$191974.0 in Q3 2025 per SIGY's latest filing, from -$981674.0 in the prior quarter.
- Over five years, Non Operating Income peaked at -$44808.0 in Q4 2024 and troughed at -$981674.0 in Q2 2025.
- A 5-year average of -$294036.5 and a median of -$192862.0 in 2022 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2023 and 2024: Non Operating Income tumbled 1091.36% in 2023, then jumped 90.23% in 2024.
- Over 5 years, Non Operating Income stood at -$636233.0 in 2021, then jumped by 39.12% to -$387349.0 in 2022, then decreased by 18.45% to -$458814.0 in 2023, then surged by 90.23% to -$44808.0 in 2024, then plunged by 328.44% to -$191974.0 in 2025.
- According to Business Quant data, Non Operating Income over the past three periods registered -$191974.0, -$981674.0, and -$122505.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Sigyn Therapeutics | 48,161.31 | -37,409.69 | - | -191,974.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -191,974.00 |
| Jun 30, 2025 | -981,674.00 |
| Mar 31, 2025 | -122,505.00 |
| Dec 31, 2024 | -44,808.00 |
| Sep 30, 2024 | -388,465.00 |
| Jun 30, 2024 | -259,578.00 |
| Mar 31, 2024 | -128,116.00 |
| Dec 31, 2023 | -458,814.00 |
| Sep 30, 2023 | -262,912.00 |
| Jun 30, 2023 | -149,115.00 |
| Mar 31, 2023 | -819,778.00 |
| Dec 31, 2022 | -387,349.00 |
| Sep 30, 2022 | -192,862.00 |
| Jun 30, 2022 | -133,530.00 |
| Mar 31, 2022 | -68,810.00 |
| Dec 31, 2021 | -636,233.00 |
| Sep 30, 2021 | -92,541.00 |
| Jun 30, 2021 | -208,043.00 |
| Mar 31, 2021 | -59,586.00 |
| Dec 31, 2020 | -107,455.00 |